Recruiting
Phase 2

EV & P

Sponsor:

Fox Chase Cancer Center

Code:

NCT07221942

Conditions

Metastatic Urothelial Carcinoma

Unresectable Urothelial Carcinoma

Advanced Urothelial Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Enfortumab vedotin

Pembrolizumab

Study Details

Brief summary:

This is a single-arm, open-label, non-randomized Phase II trial evaluating the efficacy of induction therapy with enfortumab vedotin (EV) plus pembrolizumab (P) for 18 weeks (6 cycles), followed by maintenance pembrolizumab in treatment-naïve patients with metastatic urothelial carcinoma (mUC). Approximately 97 patients will be enrolled. Induction consists of EV (1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle; starting dose of 1 mg/kg allowed) and P (200 mg IV on Day 1 of each cycle). Radiographic assessments occur after 3 and 6 cycles. Patients achieving complete or partial response transition to maintenance P (400 mg IV every 6 weeks or 200 mg IV every 3 weeks) for up to 2 years. Dose modifications for EV are permitted per protocol; no dose adjustments for P. Treatment continues until disease progression, unacceptable toxicity, or completion of maintenance therapy. Patients will enter long-term or survival follow-up as applicable.

Conditions

Metastatic Urothelial Carcinoma

Unresectable Urothelial Carcinoma

Advanced Urothelial Carcinoma

Study ID

NCT07221942

Start date

Jan 23, 2026

Status verified date

Feb, 2026

Completion date

Sep 3, 2029

Anticipated

Primary completion date

Sep 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients must have histologically and radiographically confirmed locally advanced, unresectable urothelial carcinoma.
  • Patients should not have received prior systemic therapy for metastatic disease.
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v1.1
  • Patients may have received prior neoadjuvant or adjuvant immune checkpoint inhibitor therapy for localized disease and are eligible if they completed the treatment ≥12 months prior to initiating treatment on this clinical trial.
  • ECOG performance status 0-2
  • Ability to understand and willingness to sign a written informed consent and HIPAA consent document
  • Archival tumor biospecimen (when available) must be procured for correlative evaluation. If tumor tissue is not available or accessible despite good faith efforts, patient may still be treated on study. Formalin fixed, paraffin embedded (FFPE) tissue block(s) or at least 25 unbaked, unstained slides are required. Tissue samples taken from a metastatic lesion prior to the start of screening are acceptable.
  • Normal organ and marrow function as defined below.

  • Absolute neutrophil count > 1,000/mm3 unless patient has constitutional neutropenia
  • Platelets > 100,000/µl
  • Hemoglobin > 8.0 g/dL
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 x upper limit of normal (ULN) or <3.5 x ULN if liver metastases
  • Creatinine Clearance >20 ml/min

Exclusion Criteria:

  • Patients who have received prior monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs) for urothelial cancer.
  • Grade 2 or higher baseline sensory or motor neuropathy.
  • Uncontrolled diabetes (HbA1c >8%)
  • Patients with uncontrolled and untreated central nervous system (CNS) metastases.

  • Prior radiation to CNS metastases is permitted.
  • Prior history of CNS disease that has responded to previous systemic therapy is permitted only if no recurrence.
  • Patient should not have leptomeningeal disease
  • CNS metastases have been clinically stable for at least 6 weeks prior to screening and baseline scans show no evidence of new or enlarged metastasis.
  • If requiring steroid treatment for CNS metastases, the patient is on stable dose < 10 mg/day of prednisone or equivalent for at least 2 weeks prior to starting treatment
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active untreated infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would substantially impair the patient's ability to comply with study requirements. Efforts should be made to provide reasonable accommodations before determining exclusion based on social limitations.
  • Subjects with a history of another invasive malignancy within 3 years before the first dose of study drug that cannot be watched and requires treatment, or any evidence of residual disease from a previously diagnosed malignancy that cannot be watched and requires treatment. Adjuvant hormonal therapy for breast cancer is allowed.
  • Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of enfortumab vedotin. Routine antimicrobial prophylaxis is permitted.
  • Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with enfortumab vedotin.
  • History of idiopathic pulmonary fibrosis; organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
  • Prior allogeneic stem cell or solid organ transplant.
  • Other underlying medical condition that, in the opinion of the investigator, would impair the ability of the patient to receive or tolerate the planned treatment and follow-up; any known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the study.
  • Patients with active tuberculosis.
  • Pregnant or breast feeding
  • History of autoimmune diseases. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., use of disease modifying agents, corticosteroids, or immunosuppressive drugs).

  • Patients with vitiligo or residual autoimmune hypothyroidism on stable doses of hormone replacement are permitted to enroll.
  • Patients with type 1 diabetes mellitus (T1DM) on a stable dose of insulin are permitted to enroll.
  • Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
  • On high dose steroids at the time of study enrollment, defined as >10 mg prednisone (or bioequivalent), including steroids used for management of intracranial lesions. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.
  • Patients who received prior immunotherapy for mUC or for an alternative malignancy are eligible unless they developed an immune related adverse event while on therapy requiring cessation of therapy or use of disease modifying agents, corticosteroids, or immunosuppressive drugs.

Study Design

Enrollment

97 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Induction EV + Pembrolizumab Followed by Maintenance Pembrolizumab

Participants will receive induction therapy with enfortumab vedotin (EV) plus pembrolizumab (P) for 6 cycles (approximately 18 weeks). EV will be administered at 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle (starting dose of 1 mg/kg allowed), and pembrolizumab at 200 mg IV on Day 1 of each cycle. Patients achieving complete or partial response will transition to maintenance pembrolizumab at 400 mg IV every 6 weeks or 200 mg IV every 3 weeks for up to 2 years. Dose modifications for EV are permitted per protocol; no dose adjustments for pembrolizumab. Treatment continues until disease progression, unacceptable toxicity, or completion of maintenance therapy.

Interventions

Enfortumab vedotin

EV will be administered at 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle

Pembrolizumab

Pembrolizumab will be administered at 200 mg IV on Day 1 of each 21-day cycle

Primary outcome measure

  • 18-month progression-free survival (PFS) [ Time Frame: 18 months ]

Central Contacts and Locations

Central contacts

Ryan Romasko, MBA

215-214-1515ryan.romasko@fccc.edu

Locations

Fox Chase Cancer Center - Philadelphia

Recruiting

Philadelphia, Pennsylvania, United States, 19111-2497

Contacts

Pooja Ghatalia, MD

Pooja.Ghatalia@tuhs.temple.edu

More Information

Sponsor

Fox Chase Cancer Center

Last update posted

Feb 19, 2026

Last verified

Feb, 2026

Keywords

  • Urothelial carcinoma

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Fox Chase Cancer Center on 2026-02-19.